RT Journal Article
SR Electronic
T1 The Role of CRP, Interleukin-6 and Their Derived Immune-Inflammatory Indices in Early Prediction of Severity and Mortality of COVID-19 Patients
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.06.28.21259644
DO 10.1101/2021.06.28.21259644
A1 Taha, Sara I.
A1 Shata, Aalaa K.
A1 El-Sehsah, Eman M.
A1 Fouad, Shaimaa H.
A1 Moussa, Aya H.
A1 Abdalgeleel, Shaimaa A.
A1 Moustafa, Nouran M.
A1 Youssef, Mariam K.
YR 2021
UL http://medrxiv.org/content/early/2021/11/05/2021.06.28.21259644.abstract
AB Background In coronavirus disease 2019 (COVID-19), finding sensitive biomarkers is critical for detecting severe cases early and intervening effectively.Objectives To compare and evaluate the predictive value of C-reactive protein (CRP), interleukin-6 (IL-6), and their derived immune-inflammatory indices (CRP/albumin (CRP/alb), lymphocyte/CRP (L/CRP), and lymphocyte/IL-6 (L/IL-6)) in COVID-19 patients.Methods On admission, 85 confirmed COVID-19 patients, their measured and collected laboratory data were obtained and compared.Results Levels of CRP, IL-6, and CRP/alb were significantly higher (P=0.001) in severe patients and non-survivors, but L/CRP and L/IL-6 were significantly lower (P=0.001). We observed the best predictive performance for COVID-19 severity at 1.65 for CRP/alb and 260.86 for L/CRP with 84.7% diagnostic accuracy for both. The best diagnostic accuracy for COVID-19 in-hospital mortality was 87.1% by IL-6 at 120 pg/ml and 85.9% by L/IL-6 at 5.40. The multi-marker prediction surpassed the performance of a single biomarker prediction. IL-6 was an independent risk factor associated with severe disease development (odds ratio (OR): 1.033; 95% confidence interval (CI): 1.002-1.066).Conclusions Pretreatment values of CRP, IL-6, and their derived indices could be included in the diagnostic work-up of COVID-19 to determine the severity and predict the outcome.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Ain-Shams University Faculty of Medicine Research Ethics Committee (REC)I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData will be available upon request.CRP/albCRP/albuminL/CRPlymphocyte/CRPL/IL-6lymphocyte/IL-6